Asper Biotech

Vaksali 17a
Tartu 50410
Estonia

Phone: +372-7-307-295
Fax: +372-7-307-298
E-Mail: This e-mail address is being protected from spam bots, you need JavaScript enabled to view it

Description:

Asper Biotech is a genetic testing company, established in 1999 as a spin-off of a research organization called the Estonian Biocentre. Since then Asper Biotech has quickly became a leading Estonian biotechnology exporter due to our extensive services and the quality of the results.

The company’s unique technology Arrayed Primer Extension (APEX) allows simultaneous, cost effective detection of hundreds DNA alterations in many different genes. In addition to APEX we offer full range of technologies such as sequencing technology and next-generation-sequencing.

Asper Biotech is an expert at developing state-of-the-art genetic tests for common and rare genetic diseases. Among others, Asper Biotech is specialized in retinal disorders, reproductive medicine and oncology. Asper Ophthalmics testing portfolio includes a comprehensive panel of tests targeting hereditary eye disorders. Asper Oncogenetics and Asper Reprogenetics offer an increasing number of tests aimed respectively to determine cancer predisposition and reproductive problems. Reprogenetical portfolio also includes tests for prenatal diagnostics.

Besides genetic diagnostic services, Asper Biotech offers custom genotyping for national and global science and research organizations. Company is an appreciated scientific partner for many international R&D projects due to the innovation-driven approach and long-lasting experience.

Asper Biotech’s laboratory is an authorized medical laboratory, CLIA (99D2046227) and ISO 9001:2008 certified. Asper Biotech is participating in the European Molecular Genetics Quality Network (EMQN) quality assessment schemes in order to obtain the external quality control for mutation scanning and improve our testing services.

Last update of this entry: February 27, 2013